Virtual reality could help spot thinking problems in MS patients

NCT ID NCT03768648

Completed Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 75 people with relapsing-remitting multiple sclerosis (RRMS) who were taking the medication Aubagio. The goal was to see if virtual reality tests and real-world tasks could better detect cognitive (thinking) problems in everyday life compared to standard tests. Researchers also used advanced MRI scans to examine brain structure and connections. The study did not test a new treatment but aimed to improve how cognitive issues are identified and tracked in MS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aubagio (teriflunomide)
What this could lead to: If successful, this could lead to better ways to detect and track cognitive problems in daily life for people with MS, using virtual reality tests.
What could go wrong: This is an observational study with no new treatment being tested. The results may not change current care, and the virtual reality tests may not prove more useful than standard assessments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disorder of the nervous system CNS demyelinating autoimmune disease Cognitive Dysfunction demyelinating disease immune system disorder multiple sclerosis nervous system disorder Pathologic Processes relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

CHU de Bordeaux - Service de neurologie

Bordeaux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.